Brain cancer breakthrough? new device zaps tumors during surgery

NCT ID NCT07141732

Recruiting now Disease control Sponsor: Joint Stock Company European Medical Centre Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests a new approach for glioblastoma, an aggressive brain cancer. During surgery to remove the tumor, doctors will use a special balloon device to deliver a single dose of radiation directly to the area. Afterward, patients will receive standard chemotherapy and radiation. The goal is to see if this combination can help people live longer. Only 15 people will take part in this pilot study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Xoft Axxent eBx System (electronic brachytherapy device)
What this could lead to: If successful, this approach could improve survival for glioblastoma patients by delivering radiation directly to the tumor site during surgery, potentially reducing recurrence.
What could go wrong: This is a very early phase 1 trial with only 15 people, so results may not apply broadly. Risks include radiation damage to healthy brain tissue, infection, or no benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Joint-Stock Company European Medical Center
RECRUITING

Moscow, Moscow, 129090, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.